The Changing Landscape of Declaratory Judgment Jurisdiction: MedImmune v. Genentech and its Federal Circuit Progeny

Similar documents
Fish & Richardson Declaratory Judgment Post-Medimmune Presentation

POST-MEDIMMUNE DEVELOPMENTS REGARDING DECLARATORY JUDGMENT JURISDICTION

Case 1:11-cv PAC Document 25 Filed 10/14/11 Page 1 of 11

A Nonrepudiating Patent Licensee s Right To Seek Declaratory Judgment of Invalidity or Noninfringement of the Licensed Patent: MedImmune v.

United States District Court, Northern District of Illinois

Life Sciences Industry Perspective on Declaratory Judgment Actions and Licensing Post-MedImmune. Roadmap for Presentation

Eccleston & Wegner, MedImmune: The Federal Circuit Fills in the Blanks

United States Court of Appeals for the Federal Circuit

Declaratory Judgment Actions in Patent Cases: The Federal Circuit's Response to MedImmune v. Genetech

Putting the Law (Back) in Patent Law

License Agreements and Litigation: Protecting Your Assets and Revenue Streams in the High-Tech and Life Science Industries

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

Stop the Bleeding: Medimmune Ends the Unjustified Erosion of Patent Holders' Rights in Patent Licensing Agreements

Infringement Assertions In The New World Order

No IN THE EISAI CO. LTD AND EISAI MEDICAL RESEARCH, INC., TEVA PHARMACEUTICALS USA, INC., through its GATE PHARMACEUTICALS Division,

intellectual property law ideas on License to sue Virtually liable Heavy lifting Copyright Office allows expanded DMCA circumvention

Patent Trial and Appeal Board Patent and Trademark Office (P.T.O.) *1 ARIOSA DIAGNOSTICS. PETITIONER, v. ISIS INNOVATION LIMITED PATENT OWNER.

2010 Thomson Reuters. No Claim to Orig. US Gov. Works.

Oklahoma Law Review. John M. Bunting. Volume 62 Number 2

UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT

No FOREST LABORATORIES, INC., FORES~LASO~TO~S Hot~mes, L~., ~D H. LU~.CK A/S, Petitioners,

Reverse Patent Declaratory Judgment Actions: A Proposed Solution for Medtronic

SUPREME COURT OF THE UNITED STATES

Patent Enforcement Pre-Litigation Considerations

United States Court of Appeals for the Federal Circuit

Supreme Court of the United States

United States Court of Appeals for the Federal Circuit

The Patentee and Infringer Battlefront Worsens as Courts Sharpen the Infringer s Sword

Summary of LES lecture (full text below)

Proveris Scientific Corp. v. Innovasystems, Inc.

AMERICA INVENTS ACT. Changes to Patent Law. Devan Padmanabhan Shareholder, Winthrop & Weinstine

The Patentee and Infringer Battlefront Worsens as Courts Sharpen the Infringer's Sword

Case 3:06-cv JSW Document 203 Filed 02/12/2008 Page 1 of 6

TABLE OF CONTENTS TABLE OF CONTENTS...i TABLE OF AUTHORITIES... iii INTEREST OF THE AMICI...1 SUMMARY OF THE ARGUMENT...3 ARGUMENT...4 I.

No IN THE Supreme Court of the United States. ALREADY, LLC d/b/a YUMS, NIKE, INC.,

United States Court of Appeals for the Federal Circuit

United States Court of Appeals for the Federal Circuit

RECENT FEDERAL CIRCUIT DECISIONS ASSESSING JURISDICTION Richard Basile Partner St. Onge Steward Johnston & Reens LLC Stamford CT

Recent Decisions Impacting Patent Litigation*

Paper 15 Tel: Entered: July 28, 2015 UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

America Invents Act (AIA) The Patent Reform Law of 2011 Initial Summary

America Invents Act (AIA) Post-Grant Proceedings

USPTO Post Grant Trial Practice

United States Court of Appeals for the Federal Circuit

Teva v. EISAI: What's the Real Controversy

Case 3:18-cv GAG Document 33 Filed 10/17/18 Page 1 of 7 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF PUERTO RICO OPINION AND ORDER

The Death of the Written Description Requirement? Analysis and Potential Outcomes of the Ariad Case

PENDING LEGISLATION REGULATING PATENT INFRINGEMENT SETTLEMENTS

United States Court of Appeals For the Eighth Circuit

Case 1:15-cv ILG-SMG Document 204 Filed 12/05/18 Page 1 of 13 PageID #: : : Plaintiff, : : : : : INTRODUCTION

ORDER GRANTING IN PART AND DENYING IN PART MOTION TO TRANSFER OR STAY

Intellectual Property Licensing Strategies

Standing to Sue in the Myriad Genetics Case

Freedom to Operate and Selected Issues

The Roadblock for Generic Drugs: Declaratory Judgment Jurisdiction for Later Generic Challengers

United States Court of Appeals for the Federal Circuit

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION, AKRON

Robert D. Katz, Esq. Eaton & Van Winkle LLP 3 Park Avenue 16th Floor New York, N.Y Tel: (212)

From PLI s Program New Strategies Arising from the Hatch-Waxman Amendments #4888

SUCCESSFULLY LITIGATING METHOD OF USE PATENTS IN THE U.S.

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS. Case No. COMPLAINT FOR DECARATORY RELIEF

TECHNOLOGY & BUSINESS LAW ADVISORS, LLC

Nicholas Roper TABLE OF CONTENTS

In The Supreme Court of the United States

Do-Overs: Overviewing the Various Mechanisms for Reevaluating an Issued Patent and How They Have Changed Over the Last Five Years +

: : : : In its Second Amended Complaint, Plaintiff The Velvet Underground ( VU ) seeks, inter

Microsoft Corp. v. i4i L.P. et al. U.S. Supreme Court (No )

Case 3:14-cv MLC-TJB Document Filed 07/24/15 Page 2 of 16 PageID: 1111 TABLE OF CONTENTS INTRODUCTION... 1 BACKGROUND...

Case 1:16-cv UNA Document 1 Filed 04/07/16 Page 1 of 17 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) )

Some Declaratory Judgment Guidance For ANDA Litigants

Intellectual Property Law

United States Court of Appeals for the Federal Circuit

SUPREME COURT OF THE UNITED STATES

FEDERAL CIRCUIT DECISIONS FOR WEEK ENDING June 19, 2015

SCA Hygiene Prods. v. First Quality Baby Prods.

Anthony C Tridico, Ph.D.

Induced and Divided Infringement: Updates and Strategic Views

IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF NORTH CAROLINA

PATENT CASES AND PUBLIC CONTROVERSIES

Injunctive Relief in U.S. Courts

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF INDIANA INDIANAPOLIS DIVISION ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

2011 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

Case 3:11-cv JAP -TJB Document 32 Filed 07/06/11 Page 1 of 19 PageID: 530 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

Patent Invalidation Defense v. Correction of Claims Counter-Assertion in Patent Infringement Litigation

2008 Federal Circuit

Terminating Inter Partes Review Proceedings Before the Patent Trial and Appeal Board

LIMELIGHT V. AKAMAI: LIMITING INDUCED INFRINGEMENT

RESPONSE. Standing to Challenge Patents, Enforcement Risk, and Separation of Powers

License Agreements in the Wake of Quanta: A Potential Need for Restructuring

SUPREME COURT OF THE UNITED STATES

No UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT

SCA Hygiene (Aukerman Laches): Court Grants En Banc Review

No IN THE UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT WART-HOG WANDS, INC., T. FIDDLE, INC.,

Case 2:11-cv WHW -MCA Document 7 Filed 09/12/11 Page 1 of 17 PageID: 57

Case 1:10-cv NMG Document 224 Filed 01/24/14 Page 1 of 9. United States District Court District of Massachusetts

United States Court of Appeals for the Federal Circuit

Chapter 13 Enforcement and Infringement of Intellectual Property Rights

AUBURN UNIVERSITY OFFICE OF INNOVATION ADVANCEMENT AND COMMERCIALIZATION. Ready To Sign non-exclusive licensing program

Inter Partes Review vs. District Court Litigation

Case 1:15-cv MAK Document 44 Filed 10/10/17 Page 1 of 13 PageID #: 366 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

Transcription:

The Changing Landscape of Declaratory Judgment Jurisdiction: MedImmune v. Genentech and its Federal Circuit Progeny

Where are we now? Jan. 9, 2007 Supreme Court decides MedImmune v. Genentech March 26, 2007 Federal Circuit decides SanDisk v. STMicroelectronics March 30, 2007 Federal Circuit decides Teva Pharmaceuticals v. Novartis Pharmaceuticals Federal Circuit reacts 2

Where are we now? (cont.) Aug. 3, 2007 Federal Circuit decides Sony Electronics v. Guardian Federal Circuit reacts 3

Supreme Court: MedImmune v. Genentech Decided January 9, 2007 8-1, with Justice Scalia delivering the opinion of the Court and Justice Thomas dissenting Reversed a Federal Circuit decision and effectively overruled Gen-Probe v. Vysis that a patent licensee must terminate or breach the license in order to create a case or controversy to support an action for declaratory judgment 4

Supreme Court: MedImmune v. Genentech (cont.) No bright-line test: Supreme Court declaratory judgment case law does not draw the brightest of lines between those declaratory-judgment actions that satisfy the case-orcontroversy requirement and those that do not. Announced the All Circumstances Test: Basically, the question in each case is whether the facts alleged, under all the circumstances, show that there is a substantial controversy, between parties having adverse legal interests, of sufficient immediacy and reality to warrant the issuance of a declaratory judgment. 5

Supreme Court: MedImmune v. Genentech (cont.) The Court criticized the Federal Circuit, in footnote 11, noting that the Federal Circuit s reasonable apprehension of suit test conflicts with multiple Supreme Court cases: Altvater v. Freeman, 319 U.S. 359 (1943) Maryland Casualty Co. v. Pacific Coal & Oil Co., 312 U.S. 270, 273 (1941) Aetna Life Ins. Co. v. Haworth, 300 U.S. 227, 239 (1937) Cardinal Chemical Co. v. Morton Int l, Inc., 508 U.S. 83, 98 (1993) 6

Supreme Court: MedImmune v. Genentech: Facts MedImmune accepted a license obliging payment of royalties for any drug covered by patent(s) issued from certain pending patent applications License provided that MedImmune was obliged to pay royalties until patent was held invalid in unappealable, final judgment License did not bar MedImmune from challenging patent s validity When patent issued, Genentech sent letter demanding royalty payments MedImmune replied stating patent was believed to be invalid and unenforceable 7

Supreme Court: MedImmune v. Genentech: Facts (cont.) MedImmune paid royalties under protest and with reservation of all of its rights MedImmune filed declaratory judgment action on contractual rights and obligations, alleging that its drug did not infringe and did not infringe any valid claim Federal Circuit applied Gen-Probe and held that a licensee in good standing can have no reasonable apprehension of suit and affirmed the district court s dismissal of the declaratory judgment action 8

Supreme Court: MedImmune v. Genentech: Holding The underlying DJ action was interpreted to be both a contract dispute and a validity challenge The issue: The factual and legal dimensions of the dispute are well defined and, but for petitioner s continuing to make royalty payments, nothing about the dispute would render it unfit for judicial resolution. Citing Altvater v. Freeman, 319 U.S. 359 (1943), the Court held that a licensee s failure to cease its payment of royalties did not render nonjusticiable a dispute over the validity of the patent 9

Federal Circuit: SanDisk v. STMicroelectronics Decided March 26, 2007 Judge Linn authored panel decision Relying on footnote 11 of MedImmune, the court abolished the reasonable apprehension of suit test prong of the Federal Circuit s former two-part test for declaratory judgment Judge Bryson Judge Linn Judge Dyk 10

Federal Circuit: SanDisk v. STMicroelectronics: Facts Context: license negotiations SanDisk filed declaratory judgment for noninfringement or invalidity with respect to various STMicroelectronics patents 11

Federal Circuit: SanDisk v. STMicroelectronics: Facts (cont.) SanDisk established the requisite case or controversy because ST sought a right to a royalty under its patents based on specific, identified activity by SanDisk, including: STMicroelectronics presentation of a thorough, element-by-element infringement analysis by seasoned litigation experts as part of license negotiations STMicroelectronics liberal discussion of SanDisk s present, ongoing infringement of STMicroelectronics patents and the need for SanDisk to license those patents during negotiations 12

Federal Circuit: SanDisk v. STMicroelectronics: Facts (cont.) Exchange of material including copies of patents, reverse engineering reports, and infringement analysis diagrams STMicroelectronics communication that it had a right to a royalty SanDisk s insistence it could proceed without paying royalties 13

Federal Circuit: SanDisk v. STMicroelectronics: Holding Federal Circuit adopts all circumstances test: We need not define the outer boundaries of declaratory judgment jurisdiction, which will depend on the application of the principles of declaratory judgment jurisdiction to the facts and circumstances of each case. 14

Federal Circuit: SanDisk v. STMicroelectronics: Holding (cont.) We hold only that where a patentee asserts rights under a patent based on certain identified ongoing or planned activity of another party, and where that party contends that it has the right to engage in the accused activity without license, an Article III case or controversy will arise and the party need not risk a suit for infringement by engaging in the identified activity before seeking a declaration of legal rights. 15

Federal Circuit: SanDisk v. STMicroelectronics: Holding (cont.) Footnote 1: Suitable confidentiality agreements can avoid the risk of a declaratory judgment action Rule 408 is not sufficient to prevent use of negotiation communications as a basis for declaratory judgment jurisdiction 16

Federal Circuit: Teva v. Novartis Judge Mayer Judge Friedman Decided March 30, 2007 Judge Gajarsa authored panel decision Relying on MedImmune s all the circumstances test and acknowledging footnote 11, indicating the Federal Circuit s former two-part test for declaratory judgment conflicts or would contradict several Supreme Court cases, the court adopts the all the circumstances test Judge Gajarsa 17

Federal Circuit: Teva v. Novartis, Facts Teva filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic drug and certified as part of the ANDA application that its drug did not infringe any of Novartisrelated patents or that the patents were invalid Novartis filed suit for infringement for only one of its patents Teva filed a declaratory judgment action on other related therapeutic use patents 18

Federal Circuit: Teva v. Novartis, Holding We hold that under all the circumstances as found in this case, Teva has an injury-in-fact and therefore has a justiciable Article III controversy. 19

Declaratory Judgment: All the Circumstances in lieu of reasonable apprehension of suit prong of the Federal Circuit s former two-part test where a patentee asserts rights under a patent based on certain identified ongoing or planned activity of another party, and where that party contends that it has the right to engage in the accused activity without license, an Article III case or controversy will arise -- SanDisk v. STMicroelectronics 20

A glimpse of things to come?????? Jan. 9, 2007 Supreme Court decides MedImmune v. Genentech March 26, 2007 Federal Circuit decides SanDisk v. STMicroelectronics March 30, 2007 Federal Circuit decides Teva Pharmaceuticals v. Novartis Pharmaceuticals Concurrence by Judge Bryson Federal Circuit reacts Concurrence by Judge Friedman 21

SanDisk v. STMicroelectronics: Concurrence by Judge Bryson Judge Bryson The footnote in MedImmune calls our case law into question and would appear to make declaratory judgments more readily available to parties who are approached by patentees seeking to license their patents. But the rule adopted by the court will effect a sweeping change in our law regarding declaratory judgment jurisdiction. It would appear that under the court s standard, a declaratory judgment action would be allowed in virtually any case in which the recipient of an invitation to take a patent license elects to dispute the need for a license and then to sue the licensee. 22

Teva v. Novartis: Concurrence by Senior Judge Friedman Judge Friedman In these unusual circumstances, where the Supreme Court went out of its way to state its disagreement with our reasonable apprehension of imminent suit test, which was not an issue in the case before it, it appears incumbent on us to stop using that test and hereinafter to apply the general declaratory judgment standards that the Supreme Court applied in MedImmune. 23

Federal Circuit: Additional Cases Aug. 3, 2007 Federal Circuit decides Sony Electronics v. Guardian 24

Federal Circuit: Sony Electronics v. Guardian Media Technologies Decided August 3, 2007 Judge Prost authored panel decision Relying on MedImmune and acknowledging SanDisk and Teva, the court vacates and remands for the district court to determine whether to entertain the declaratory judgment suits Judge Newman Judge Friedman Judge Prost 25

Federal Circuit: Sony Electronics v. Guardian Media Technologies: Facts Context: license negotiations Sony, Matsushita and Mitsubishi and Thomson each filed a declaratory judgment for noninfringement, invalidity and unenforceable due to laches and equitable estoppel with respect to various Guardian patents related to parental rating control technology for televisions and DVD products JVC also filed a declaratory judgment suit against Guardian Sony, Matsushita, Mitsubishi and JVC filed a request for ex parte reexamination of the patents-in-suit after filing their complaints 26

Federal Circuit: Sony Electronics v. Guardian Media Technologies: Holding with Regard to Sony Sony established the requisite case or controversy because the parties had taken adverse positions regarding whether Sony s sale of products infringed any valid claims of the patents-in-suit Guardian identified certain Sony products that allegedly infringed the patents-in-suit» Provided detailed claim charts» Asserted entitlement to royalties of $31M Guardian communicated its position that prior art identified by Sony did not invalidate the patentsin-suit 27

Federal Circuit: Sony Electronics v. Guardian Media Technologies: Holding with Regard to Matsushita & JVC Matsushita and JVC established the requisite case or controversy because the parties had taken adverse positions regarding whether Matsushita s and JVC s sale of products infringed any valid claims of the patents-in-suit Guardian provided detailed infringement analyses of patent claims to Matsushita s and JVC s identified products» Provided detailed claim charts» Asserted entitlement to royalties exceeding $25M Matsushita and JVC maintained patents-in-suit were invalid as anticipated by certain identified prior art references 28

Federal Circuit: Sony Electronics v. Guardian Media Technologies: Holding with Regard to Mitsubishi Mitsubishi established the requisite case or controversy because the parties had taken adverse positions regarding whether Mitsubishi s sale of products infringed any valid claims of the patents-in-suit Guardian conveyed that any Mitsubishi product having V-chip functionality infringed the patents-in-suit» Identified specific models that allegedly supported V-chip functionality» Offered a fully paid-up license for $4M which would cover every V-chip enabled product sold by Mitsubishi Mitsubishi maintained it did not need a license because the patents-in-suit were invalid in view of certain identified prior art references 29

Federal Circuit: Sony Electronics v. Guardian Media Technologies: Holding Because Guardian asserts that it is owed royalties based on specific past and ongoing activities by Sony, Matsushita, JVC and Mitsubishi, and because Sony, Matsushita, JVC and Mitsubishi each contend that it has a right to engage in those activities without a license, there is an actual controversy between the parties within the meaning of the Declaratory Judgment Act District court erred in dismissing the complaints for lack of subject matter jurisdiction 30

Contact Barbara A. Benoit, Ph.D. 202-626-6363 benoit@fr.com Katherine Lutton 650-839-5084 lutton@fr.com 31